ES2703052T3 - Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos - Google Patents
Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos Download PDFInfo
- Publication number
- ES2703052T3 ES2703052T3 ES13826083T ES13826083T ES2703052T3 ES 2703052 T3 ES2703052 T3 ES 2703052T3 ES 13826083 T ES13826083 T ES 13826083T ES 13826083 T ES13826083 T ES 13826083T ES 2703052 T3 ES2703052 T3 ES 2703052T3
- Authority
- ES
- Spain
- Prior art keywords
- polypeptide
- seq
- penton
- cells
- phage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims description 11
- 238000002955 isolation Methods 0.000 title description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 100
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 90
- 210000004027 cell Anatomy 0.000 claims abstract description 87
- 229920001184 polypeptide Polymers 0.000 claims abstract description 82
- 230000035772 mutation Effects 0.000 claims abstract description 29
- 210000003463 organelle Anatomy 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 21
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 13
- 241001135569 Human adenovirus 5 Species 0.000 claims abstract description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 5
- 102220526988 Tumor protein D54_L60W_mutation Human genes 0.000 claims abstract description 5
- 102200149445 rs1800367 Human genes 0.000 claims abstract description 5
- 102220196427 rs781394318 Human genes 0.000 claims abstract description 5
- 102220029527 rs78540316 Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 37
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims description 35
- 108091033319 polynucleotide Proteins 0.000 claims description 27
- 102000040430 polynucleotide Human genes 0.000 claims description 27
- 239000002157 polynucleotide Substances 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 14
- 210000004940 nucleus Anatomy 0.000 claims description 12
- 230000001131 transforming effect Effects 0.000 claims description 10
- 102400000058 Neuregulin-1 Human genes 0.000 claims description 9
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 9
- 229940126585 therapeutic drug Drugs 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 238000002703 mutagenesis Methods 0.000 claims description 6
- 231100000350 mutagenesis Toxicity 0.000 claims description 6
- 108010039918 Polylysine Proteins 0.000 claims description 5
- 108700025771 adenovirus penton Proteins 0.000 claims description 5
- 210000000172 cytosol Anatomy 0.000 claims description 5
- 229920000656 polylysine Polymers 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 210000000805 cytoplasm Anatomy 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000598171 Human adenovirus sp. Species 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 3
- 210000002288 golgi apparatus Anatomy 0.000 claims description 3
- 210000003470 mitochondria Anatomy 0.000 claims description 3
- 210000003705 ribosome Anatomy 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 description 26
- 239000012528 membrane Substances 0.000 description 16
- 230000035515 penetration Effects 0.000 description 13
- 230000001086 cytosolic effect Effects 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000000394 mitotic effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000009510 drug design Methods 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 230000010189 intracellular transport Effects 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 101710173835 Penton protein Proteins 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000000021 endosomolytic effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 230000004942 nuclear accumulation Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027755 Blood autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101710168537 High mobility group protein B1 Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001188 anti-phage Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000032895 autoimmune disorder of blood Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 108010084091 heregulin beta1 Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VDXZNPDIRNWWCW-UHFFFAOYSA-N melitten Chemical compound NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-UHFFFAOYSA-N 0.000 description 1
- 238000000409 membrane extraction Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ecology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679306P | 2012-08-03 | 2012-08-03 | |
| PCT/US2013/053493 WO2014022811A1 (en) | 2012-08-03 | 2013-08-02 | Isolating traffic-enhancing mutants of drug delivery protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2703052T3 true ES2703052T3 (es) | 2019-03-06 |
Family
ID=50028570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13826083T Active ES2703052T3 (es) | 2012-08-03 | 2013-08-02 | Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos |
Country Status (18)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9078927B2 (en) | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| EP2880160B1 (en) * | 2012-08-03 | 2018-09-19 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
| CN106413738B (zh) | 2014-01-17 | 2020-12-29 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| RU2692104C2 (ru) | 2014-04-04 | 2019-06-21 | Сидарс-Синай Медикал Сентр | Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439829A (en) | 1991-01-30 | 1995-08-08 | Eli Lilly And Company | Immobilization of biologically active molecules by changing the Oxidation state of a chelated transition metal ion |
| US6287792B1 (en) | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5547945A (en) | 1993-07-15 | 1996-08-20 | Jcr Pharmaceuticals Co., Ltd. | Remitting agent for nephrotic syndrome and hepatopathy symptoms |
| US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US6465253B1 (en) * | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| CZ162398A3 (cs) * | 1995-11-28 | 1998-10-14 | Gen Vec, Inc. | Vektory a způsoby pro genový přenos do buněk |
| JP4515542B2 (ja) | 1997-02-10 | 2010-08-04 | ジェネンテック， インコーポレイテッド | ヒレグリン変異体 |
| GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| NZ509271A (en) | 1998-08-18 | 2003-10-31 | Univ California | Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| CA2391534A1 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| WO2001096871A2 (en) | 2000-06-16 | 2001-12-20 | Martek Biosciences Corporation | Recombinant phycobiliprotein and phycobiliprotein linker fusion proteins and uses therefore |
| IT1318704B1 (it) * | 2000-09-22 | 2003-08-27 | Consorzio Interuniversitario P | Vettori chimerici e loro uso per il trasferimento di geni eterologhi. |
| AU2002240201A1 (en) | 2001-02-02 | 2002-08-19 | Yale University | Peptides for facilitating composite receptor expression and translocation of macromolecules |
| EP1266963A1 (en) * | 2001-06-15 | 2002-12-18 | Crucell Holland B.V. | Chimaeric phages |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US7329638B2 (en) | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
| US7205387B2 (en) | 2003-08-28 | 2007-04-17 | Agency For Science, Technology And Research | Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist |
| WO2005117928A1 (en) | 2004-05-30 | 2005-12-15 | Cemines, Inc. | Compositions and methods for the treatment of skin cancer |
| US8057821B2 (en) | 2004-11-03 | 2011-11-15 | Egen, Inc. | Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof |
| WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| JP4479755B2 (ja) | 2007-07-03 | 2010-06-09 | ソニー株式会社 | 有機エレクトロルミネッセンス素子、及び、有機エレクトロルミネッセンス表示装置 |
| US9078927B2 (en) * | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
| AU2008331906B2 (en) * | 2007-11-28 | 2014-03-06 | The Trustees Of The University Of Pennsylvania | Simian E adenovirus SAdV-39 |
| WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
| EP2764011B1 (en) | 2011-10-05 | 2021-04-07 | GenVec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| EP2880160B1 (en) | 2012-08-03 | 2018-09-19 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
| US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
| CN106413738B (zh) * | 2014-01-17 | 2020-12-29 | 席德-西奈医疗中心 | 受体靶向构造物和其使用 |
| RU2692104C2 (ru) * | 2014-04-04 | 2019-06-21 | Сидарс-Синай Медикал Сентр | Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц |
| EA201892797A1 (ru) * | 2016-05-27 | 2019-06-28 | Седарс-Синаи Медикал Сентер | Наночастицы для доставки лекарственных средств и способы лечения лекарственно-резистентного рака |
-
2013
- 2013-08-02 EP EP13826083.1A patent/EP2880160B1/en not_active Not-in-force
- 2013-08-02 KR KR1020157005438A patent/KR102115630B1/ko not_active Expired - Fee Related
- 2013-08-02 BR BR112015002004A patent/BR112015002004A2/pt not_active Application Discontinuation
- 2013-08-02 PL PL13826083T patent/PL2880160T3/pl unknown
- 2013-08-02 ES ES13826083T patent/ES2703052T3/es active Active
- 2013-08-02 JP JP2015525636A patent/JP6618360B2/ja not_active Expired - Fee Related
- 2013-08-02 WO PCT/US2013/053493 patent/WO2014022811A1/en not_active Ceased
- 2013-08-02 DK DK13826083.1T patent/DK2880160T3/en active
- 2013-08-02 AU AU2013296218A patent/AU2013296218B2/en not_active Ceased
- 2013-08-02 MX MX2015001366A patent/MX366347B/es active IP Right Grant
- 2013-08-02 PT PT13826083T patent/PT2880160T/pt unknown
- 2013-08-02 US US14/419,233 patent/US10036009B2/en active Active
- 2013-08-02 CN CN201380041215.1A patent/CN104619839A/zh active Pending
- 2013-08-02 CA CA2881582A patent/CA2881582A1/en not_active Abandoned
- 2013-08-02 RU RU2015105052A patent/RU2015105052A/ru not_active Application Discontinuation
-
2015
- 2015-01-28 IL IL236955A patent/IL236955A0/en unknown
- 2015-02-02 ZA ZA2015/00739A patent/ZA201500739B/en unknown
- 2015-02-13 IN IN1196DEN2015 patent/IN2015DN01196A/en unknown
-
2018
- 2018-06-25 US US16/017,866 patent/US10752893B2/en active Active
-
2019
- 2019-07-04 AU AU2019204815A patent/AU2019204815A1/en not_active Abandoned
- 2019-07-18 JP JP2019132760A patent/JP2020002138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN01196A (cg-RX-API-DMAC7.html) | 2015-06-26 |
| JP2015527343A (ja) | 2015-09-17 |
| JP6618360B2 (ja) | 2019-12-11 |
| MX2015001366A (es) | 2015-08-13 |
| KR102115630B1 (ko) | 2020-05-27 |
| AU2019204815A1 (en) | 2019-07-25 |
| US20150240231A1 (en) | 2015-08-27 |
| AU2013296218A1 (en) | 2015-02-19 |
| US20180298376A1 (en) | 2018-10-18 |
| JP2020002138A (ja) | 2020-01-09 |
| IL236955A0 (en) | 2015-03-31 |
| US10752893B2 (en) | 2020-08-25 |
| US10036009B2 (en) | 2018-07-31 |
| PL2880160T3 (pl) | 2019-03-29 |
| BR112015002004A2 (pt) | 2017-07-04 |
| AU2013296218B2 (en) | 2019-07-18 |
| PT2880160T (pt) | 2018-12-17 |
| CA2881582A1 (en) | 2014-02-06 |
| CN104619839A (zh) | 2015-05-13 |
| WO2014022811A1 (en) | 2014-02-06 |
| MX366347B (es) | 2019-07-05 |
| EP2880160B1 (en) | 2018-09-19 |
| EP2880160A1 (en) | 2015-06-10 |
| DK2880160T3 (en) | 2019-01-14 |
| EP2880160A4 (en) | 2016-04-20 |
| ZA201500739B (en) | 2018-07-25 |
| KR20150038543A (ko) | 2015-04-08 |
| RU2015105052A (ru) | 2016-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2703052T3 (es) | Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos | |
| US8729038B2 (en) | Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles | |
| ES2927225T3 (es) | Composición para entrega de material genético | |
| CN114258398A (zh) | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 | |
| Lund et al. | Pseudovirions as vehicles for the delivery of siRNA | |
| JP2023524915A (ja) | 腫瘍溶解性ウイルスワクチン及びそれと免疫細胞の併用による腫瘍治療薬物 | |
| WO2013103614A1 (en) | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) | |
| US20200222506A1 (en) | Stem cells for transplantation and manufacturing method therefor | |
| Kaneda et al. | Development of HVJ envelope vector and its application to gene therapy | |
| US20220313618A1 (en) | Plant viral nucleic acid delivery particles and uses thereof | |
| US8957186B2 (en) | Recombinant protein for intracellular delivery of siRNA and composition comprising the same | |
| JP2021502822A (ja) | ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス | |
| Langel | Methods for CPP functionalization | |
| CN112759654A (zh) | 一种病毒囊膜蛋白装配系统及其方法和应用 | |
| Matin et al. | Gene Delivery | |
| JP2024503728A (ja) | 様々な状態を処置するためのペプチド治療薬を同定する方法 | |
| CN120271677A (zh) | 一种细胞新型毒力因子的功能鉴定及其应用 | |
| WO2025260044A1 (en) | Ligand-directed gene editing approaches | |
| Stauber | Transposon Based Gene Therapy as a Treatment for Cancer | |
| WO2022235723A1 (en) | Engineered extracellular vesicles | |
| Kitani et al. | Efficient In Vivo Delivery of Plasmids and Oligonucleotides Using Hemagglutinating Virus of Japan Envelope (HVJ‐E) Vector in Immunological Disease Models | |
| CN120441657A (zh) | 一种靶向性重组载体及利用其制备car-m的方法 | |
| Kritz | Peptides from phage display libraries for targeted gene delivery via the p75NTR neurotrophic receptor |